Abstract
992
Objectives: 1. Review the physiological bio-distribution patterns of 68Ga-DOTATATE. 2. Discuss the role of 68Ga-DOTATATE in the evaluation, staging, and surveillance of neuroendocrine tumor (NET). 3. Discuss the advantages of 68Ga-DOTATATE over 111In-OctreoScan and 18F-FDG PET CT in evaluation of metastatic NET. 4. Review potential pitfalls in imaging with 68Ga-DOTATATE for the evaluation of NET.
Methods: In July 2016, the FDA approved 68Ga-DOTATATE for PET/CT imaging of NET, and 68Ga-DOTATATE is anticipated to replace 111In-Octreoscan and 18F-FDG for NET. This educational exhibit aims to review and discuss 68Ga-DOTATATE with regard to imaging NETs. We will provide an image-rich review of the normal bio-distribution patterns of 68Ga-DOTATATE, and will demonstrate the superiority of the 68Ga-DOTATATE PET/CT images compared to other functional imaging using 111In-OctreoScan and 18FDG. We will illustrate potential pitfalls in the diagnosis of NETs using 68Ga-DOTATATE.
Results: N/A
Conclusion: 68Ga-DOTATATE is a recently FDA-approved radiopharmaceutical for PET/CT imaging of NET. This exhibit reviews its properties and bio-distribution, clinical applications, and advantages over well-established techniques. We expect the viewers to understand expected bio-distribution patterns, pathologic patterns, as well as the common pitfalls in interpretation.